Scarica l'app Stockscreener
23.26
1.15%
-0.27
Dopo l'orario di chiusura:
23.26
Precedente Chiudi:
$23.53
Aprire:
$23.3
Volume 24 ore:
793.80K
Relative Volume:
0.88
Capitalizzazione di mercato:
$941.79M
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
16.04
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
+5.73%
1M Prestazione:
+6.84%
6M Prestazione:
-14.23%
1 anno Prestazione:
+2.51%
Intervallo 1D:
$23.04
$23.65
Intervallo di 1 settimana:
$21.50
$23.91
Portata 52W:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
23.26 | 941.79M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Profit Review: Will Pacira BioSciences Inc benefit from seasonality2026 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn
Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm
Pacira BioSciences responds to DOMA director nominations - Investing.com Australia
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga
PCRXPacira Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Pacira spends $150M on buybacks as DOMA seeks board seats - Stock Titan
Pacira BioSciences shares rise 2% as activist pushes for CEO removal - Investing.com Canada
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - PR Newswire
Pacira BioSciences (NASDAQ:PCRX) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Liquidity Mapping Around (PCRX) Price Events - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Pacira BioSciences, Inc. $PCRX Shares Purchased by American Century Companies Inc. - MarketBeat
Earnings Beat: Does Pacira BioSciences Inc have consistent dividend growthQuarterly Profit Review & Accurate Entry/Exit Alerts - baoquankhu1.vn
Pacira (PCRX) Grants Inducement Awards to New Employees - GuruFocus
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira hands new hires 2,400 options and 5,500 stock units - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case - ChartMill
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.6%What's Next? - MarketBeat
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
Non-opioid knee pain options show 12-month relief in study - Stock Titan
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - simplywall.st
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Wall Street Zen Downgrades Pacira BioSciences (NASDAQ:PCRX) to Buy - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - simplywall.st
Pacira BioSciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-02-27 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownWhat's Next? - MarketBeat
Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating - marketscreener.com
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Q4 Earnings Call Highlights - MarketBeat
Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Releases Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Pacira BioSciences reports fourth quarter and full-year 2025 financial results - marketscreener.com
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint - MSN
Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Pacira (PCRX) Q4 2025 Earnings Call Transcript - AOL.com
Pacira Biosciences (PCRX) Projects Robust Growth in FY26 with St - GuruFocus
Pacira Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Pacira: Q4 Earnings Snapshot - marketscreener.com
Q4 2025 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):